LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc.（LENZ）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · LENZ · 截至 2025年9月30日
股东结构概览
171
机构持有人数
▲ 54 vs Q2
$1.36B
机构持仓总市值
▲ $630.47M vs Q2
31.35M
总流通股
freeFloat 87.26%
29.14M
13F 申报持股数
▲ 4.41M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
LENZ 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.18M | 14.88% | 14.88% | $194.65B | Nov 14, 2025 | — held |
ALPHA WAVE GLOBAL, LP biological products, (no diagnostic substances) | 3.61M | 12.86% | 12.86% | $168.26B | Nov 13, 2025 | — held |
VERSANT VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.66M | 9.46% | 9.46% | $123.76B | Nov 10, 2025 | NEW |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.47M | 5.25% | 5.25% | $68.62B | Nov 12, 2025 | ▲ 40.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.33M | 4.74% | 4.74% | $61.96B | Nov 7, 2025 | ▲ 39.3K |
UBS GROUP AG biological products, (no diagnostic substances) | 1.20M | 4.28% | 4.28% | $55.97B | Nov 13, 2025 | ▲ 320.1K |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 1.07M | 3.82% | 3.82% | $50.00B | Nov 14, 2025 | ▼ 643.6K |
72 INVESTMENT HOLDINGS, LLC biological products, (no diagnostic substances) | 1.02M | 3.62% | 3.62% | $47.41B | Nov 14, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 897.6K | 3.20% | 3.20% | $41.81B | Nov 14, 2025 | — held |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 863.4K | 3.07% | 3.07% | $40.22B | Nov 14, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
28
增持
+3.08M 股7
新建仓
首次建仓7
减持
−1.90M 股0
清仓
完全退出净股数变化（前50家）
+1.18M
+3.08M / −1.90M
净新增持仓人
+28
新建 7 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
LENZ 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
4
买入笔数
3
卖出笔数
1.33
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
George Jeffrey P. director | Mar 27, 2026 | Purchase | 5,592 | $8.92 | $49.9K | 5.6K | Form 4 ↗ |
Schimmelpennink Evert B. President, CEO and Secretary | Mar 27, 2026 | Purchase | 28,089 | $8.95 | $251.4K | 77.3K | Form 4 ↗ |
Chevallard Daniel R. Chief Financial Officer | Mar 27, 2026 | Purchase | 7,500 | $8.57 | $64.3K | 12.9K | Form 4 ↗ |
Olsson Shawn Chief Commercial Officer | Jan 2, 2026 | Award | 84,200 | $16.00 | $1.35M | 84.2K | Form 4 ↗ |
Odrich Marc Chief Medical Officer | Jan 2, 2026 | Award | 84,200 | $16.00 | $1.35M | 84.2K | Form 4 ↗ |
Chevallard Daniel R. Chief Financial Officer | Jan 2, 2026 | Award | 84,200 | $16.00 | $1.35M | 84.2K | Form 4 ↗ |
Schimmelpennink Evert B. President, CEO and Secretary | Jan 2, 2026 | Award | 358,100 | $16.00 | $5.73M | 358.1K | Form 4 ↗ |
Olsson Shawn Chief Commercial Officer | Nov 17, 2025 | Sale | 4,212 | $25.74 | $108.4K | 10.5K | Form 4 ↗ |
Olsson Shawn Chief Commercial Officer | Nov 17, 2025 | Sale | 5,788 | $26.37 | $152.6K | 4.7K | Form 4 ↗ |
MCCOLLUM JAMES W director | Nov 7, 2025 | Purchase | 10,500 | $22.79 | $239.3K | 10.5K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
LENZ Therapeutics, Inc.（LENZ）主要由机构投资者持有，机构持股比例约为 92.9%。公司内部人员持股约 12.74%，散户及公众持股约占剩余的 0.00%。
LENZ Therapeutics, Inc. 最大机构股东为 RA CAPITAL MANAGEMENT, L.P.，截至 September 30, 2025 持有约 4.18 million 股，占总流通股的 14.88%。
目前共有 171 家机构持有 LENZ 股票，合计持仓市值约 $1.36 billion，数据来源为最新 SEC 13F 申报。
常见问题
LENZ ownershipLENZ Therapeutics, Inc.（LENZ）主要由机构投资者持有，机构持股约 92.9%。最大股东为 RA CAPITAL MANAGEMENT, L.P.，持股比例 14.88%。内部人员持股约 12.74%。数据来源 SEC Form 13F，截至 September 30, 2025。